WO1994000112A1 - An oral formulation for gastric antibacterial treatment as well as a process thereof and the use - Google Patents

An oral formulation for gastric antibacterial treatment as well as a process thereof and the use Download PDF

Info

Publication number
WO1994000112A1
WO1994000112A1 PCT/SE1993/000521 SE9300521W WO9400112A1 WO 1994000112 A1 WO1994000112 A1 WO 1994000112A1 SE 9300521 W SE9300521 W SE 9300521W WO 9400112 A1 WO9400112 A1 WO 9400112A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation according
formulation
active
tablet
pylori
Prior art date
Application number
PCT/SE1993/000521
Other languages
French (fr)
Inventor
Karl-Erik Lennart Falk
John Albert SJÖGREN
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Priority to AU45178/93A priority Critical patent/AU4517893A/en
Publication of WO1994000112A1 publication Critical patent/WO1994000112A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Definitions

  • the invention relates to formulations for treatment of infections in the upper gastrointestinal tract especially infections caused by Helicobacter pylori, and a process for the manufacture of said formulations as well as the use thereof.
  • Said formulations give a prolonged release of antimicrobal agent(s) in the upper gastrointestinal tract.
  • H.pylori Helicobacter pylori
  • H.pylori is a recently discovered bacterium, cultured for the first time in Australia 1982 [Warren JR Lancet 1983;1:1273], which has attracted much interest due to its possible aetiological role in a number of disorders in the upper gastrointestinal tract. It is considered a major cause in the development of peptic ulcer disease [Helicobacter pylori Working Party Report. World Congress in Gastroenterology, Sydney 1990] H. pylori is accepted as the aetiological agent in most cases of chronic non-specific gastritis. Chronic active gastritis is highly correlated to H. pylori -infections.
  • H. pylori The pathogenic mechanism of H. pylori is not yet known in its details.
  • the mode of transmission is unknown but considered to be by the faecal oral route and may be waterborne.
  • H. pylori is found throughout the world but there is a higher prevalence of the organism in less developed countries and in patients with low economic status in western countries. The overall prevalence in western countries is about 52 % and increases with advancing age.
  • H. pylori is a Gram-negative microaerophilic bacterium which is about 3.5 um in length and 1 ⁇ m in diameter. Due to the presence of 4-6 flagella attached to the end of its typical S- or spiral shape form, the bacterium can move rapidly in mucus. It lives closely attached to the gastric epithelial cells beneath the mucus layer and colonises the stomach, mainly the antrum, in a patchy fashion.
  • the therapy is a combination of a bismuth preparation, metronidazole and amoxicillin or tetracycline.
  • the dosage regimen involves many tablets and there is a need of administration several times per day. This is difficult for the patient to follow and compliance has been shown to be important to achieve the high eradication rates.
  • Adverse effects, mainly due to metronidazole or bismuth are very common. About 30% of the patients have reported side effects [Axon ATR, Scand J Gastroenterol 1989;24(suppl 160):35- 38].
  • Monotherapy of different antibiotics which are known to have good effect in vitro against H. pylori is insufficiently effective in vivo.
  • Amoxicillin for example, eradicates H.pylori only in about 20% of treated patients.
  • Combination of two drugs give higher eradication rates than monotherapy.
  • Bismuth preparations bismuth subsalicyclate or colloidal bismuth subcitrate
  • amoxicillin eradicated H.pylori in 44 % of treated patients
  • bismuth + metronidazole, amoxicillin + tinidazole and amoxicillin + metronidazole in about 55 % of the patients, respectively [Chiba N, Rademaker JW, Rao BV et al. Gut 1991;32:A1220-1221 Abstract].
  • Antibacterial agents have also been combined with acid secretion inhibitors. Combinations with histamin -blockers show no improved efiect. Proton pump inhibitors e g omeprazole, which have very little anti-H .pylori efiect on its own show a synergistic effect in combination with antibiotics. A dose of 750 mg amoxicillin twice daily with 40 mg omeprazole once daily was reported to eradicate H.pylori in 54% of the patients [Unge P, Eriksson K, Bergman B. et al. Gastroenterol
  • antibiotics have relatively short duration of action and are given 3-4 times a day. Attempts to prolong the action by use of prolonged release products have generally been unsuccessful because the absorption of the antibiotic from the gastrointestinal tract is poor when administered in slow release form [Delgado Charro MB, Vila Jato JL. Int J Pharm 1992;78;35-41] Instead antibiotics are given in rapidly absorbed formulations, e g tablets or capsules. In order to achieve sufficiently long duration of action higher doses are given.
  • formulations with prolonged gastric residence time are bioadhesive systems which interact with mucus or the mucosa. Another way to prolong the residence time is swelling systems which expand in contact with the gastric fluid to a size which does not allow the system to pass through the pylorus. Further examples are formulations with very high density or systems which float on the gastric contents. It has also been observed that large non-disintegrating tablets or capsules can be retained for several hours in the stomach. The retention time in the stomach is especially prolonged when the tablet or capsule is administered together with food due to the sieving function of pylorus when the stomach is in the digestive mode [Davis SS, Hardy JG, Taylor MJ et al. Int J Pharm 1984;21:331-340]. Food also retards the emptying of tablets or pellets, but the effect is less pronounced. The critical size is reported to be about 7 mm [Khosla R. Nottingham: University of Nottingham, 1987. (Diss).]
  • the drug should be released within 1-24 h, preferably 1-6 h.
  • the product should remain in the stomach at least 2-4 h, preferably more than 6 h.
  • the major part of the drug should be released before the tablet leaves the stomach.
  • the drugs suitable for the preparations according to the invention are e.g.
  • the active agents could be in standard forms or used as salts, hydrates, esters etc. A combination of two or more of the above listed drugs may be preferable, for example to ininimize the risk for developing resistance.
  • the antimicrobial agents can also be combined with other drugs used in the treatment of acid related diseases e.g. acid pump inhibitors or Hn-blockers, such as for example omeprazole.
  • Possible formulations to be used are large non-disintegrating tablets or capsules e.g. inert matrix tablets [Hui H, Robinson JR, Lee NHL. Design and fabrication of Oral Controlled Delivery Systems. In: Robinson JR, Lee NHL, eds. Controlled Drug Delivery. Fundamentals and applications. New York: Marcel Dekker, Inc, 1987:373-432], osmotic pumps [Davis SS, Fara JW. Osmotic pumps. In: Hardy JG, Davis SS, Wilson CG, eds. Drug Delivery to the Gastrointestinal Tract. Chichester: Ellis Horwood Limited, 1989:97-109.] and membrane-coated tablets.
  • inert matrix tablets Hui H, Robinson JR, Lee NHL. Design and fabrication of Oral Controlled Delivery Systems. In: Robinson JR, Lee NHL, eds. Controlled Drug Delivery. Fundamentals and applications. New York: Marcel Dekker, Inc, 1987:373-432
  • osmotic pumps [Davis SS, Fara
  • swelling systems [Banker, US Patent + no 261,242,] floating systems [Davis SS, Stockwell AF, Taylor MJ et al. Pharm Res 1986;3:208-213.], [Washington N, Wilson CG, Greaves JL et al. Scand J Gastroenterol 1988;23:920-924], formulations with high density [Devereux JE, Newton JM, Short MB. J Pharm Pharmacol 1990;42:500-501] and mucoadhesive systems [Junginger HE. Pharm Ind 1991;53:1056-1065] prepared from e.g. polycarbophil, polyacrylic acid, methylcellulose, polyethylene oxide, chitosan, tragacanth, sodium carboxymethyl cellulose can be used.
  • an example from the above listed formulations is the inert porous matrix tablet which is obtained by mixing the drug with waxes or water insoluble polymers and with fillers and binders.
  • Paraffin, polyvinylchloride, ethylcellulose, stearylic alcohol, cetylic alcohol, carnauba wax, polyethylene, polyvinyl acetate, polymethyl methacrylate could be used as suitable diffusion retarding compounds.
  • Other excipients used in the preparations of such tablets are e.g. lactose, mannitol, calcium phosphates, magnesium stearate, hydroxypropyl methylcellulose, methylcellulose, polyvinylpyrrolidone, aluminium silicate, sodium carbonate, potassium phosphate or other suitable materials.
  • Amoxicillin sodium was mixed in a planetary mixer for 5 minutes with paraffin. The resultant mixture was then moistened for 5 minutes with a solution of ethylcellulose in isopropanol and dried. The granulate was milled through a 1.0 mm sieve and lubricated for 2 minutes with magnesium stearate.
  • the granulate was compressed to tablets on a tabletting machine fitted with 13 mm punches. Each tablet contained 415 mg amoxicillin sodium.
  • the release profile of the drug is shown in Figure 1.
  • Ethylcellulose 30 Magnesium stearate 14.1 The composition according to Example 2 was formed to modified release tablets containing 375 mg of amoxicillin/tablet.
  • the tablet were prepared in the following way:
  • Example 2 Compressed into tablets after granulation and drying as in Example 1.
  • the tablets were coated with a porous membrane coating consisting of polyvinyl chloride in acetone according to [Kallstrand G, Ekman B. J Pharm Sci 1983;72(7):772-775].
  • Micronized sucrose (particle size less than 10 um) was suspended in the polymer solution. Coating was achieved by spraying the suspension on a moving bed of tablets with an airless sprayer. Coating was continued until the weight if the coat on each tablet was 50 mg.
  • Example 4 g
  • the bioadhesive pellets were manufactured using conventional fluid-bed coating technology. Amoxicilhn trihydrate was successively coated with solutions containing chitosan and ethylcellulose, respectively.

Abstract

An oral formulation with extended release for treatment of infections in the upper gastrointestinal tract as well as processes for the preparation and the use thereof.

Description

AN ORAL FORMULATION FOR GASTRIC ANTIBACTERIAL TREATMENT AS WELL AS A PROCESS THEREOF AND THE USE
Technical field
The invention relates to formulations for treatment of infections in the upper gastrointestinal tract especially infections caused by Helicobacter pylori, and a process for the manufacture of said formulations as well as the use thereof.
Said formulations give a prolonged release of antimicrobal agent(s) in the upper gastrointestinal tract.
Background of the invention Helicobacter pylori (H.pylori) is a recently discovered bacterium, cultured for the first time in Australia 1982 [Warren JR Lancet 1983;1:1273], which has attracted much interest due to its possible aetiological role in a number of disorders in the upper gastrointestinal tract. It is considered a major cause in the development of peptic ulcer disease [Helicobacter pylori Working Party Report. World Congress in Gastroenterology, Sydney 1990] H. pylori is accepted as the aetiological agent in most cases of chronic non-specific gastritis. Chronic active gastritis is highly correlated to H. pylori -infections. The organism is found in association with chronic active gastritis in almost 100% of the cases. Further, it was concluded in a case-control study of 372 patients that infection with H. pylori is associated with an increased risk of gastric adenocarcinoma and may be a cofactor in the pathogenesis of this malignant condition [Parsonnet J, Friedman GD, Daniel MS et al. N Engl J Med 1991;325:1127-31].
The pathogenic mechanism of H. pylori is not yet known in its details. The mode of transmission is unknown but considered to be by the faecal oral route and may be waterborne. H. pylori is found throughout the world but there is a higher prevalence of the organism in less developed countries and in patients with low economic status in western countries. The overall prevalence in western countries is about 52 % and increases with advancing age.
H. pylori is a Gram-negative microaerophilic bacterium which is about 3.5 um in length and 1 μm in diameter. Due to the presence of 4-6 flagella attached to the end of its typical S- or spiral shape form, the bacterium can move rapidly in mucus. It lives closely attached to the gastric epithelial cells beneath the mucus layer and colonises the stomach, mainly the antrum, in a patchy fashion.
In vitro studies show a high sensitivity of H. pylori to many antibiotics [McNulty CA, Dent JC. Eur J Clin Microbiol Infect Dis 1988;7:566-569], [Lambert T, Megraud F, Gerbaud G et al. Antimicrob Agents Chemother 1986;30:510-511]. However, in vivo studies have demonstrated that there is a small correlation between in vitro sensitivity for H. pylori and treatment results in vivo for antibacterial drugs. The eradication regime with best eradication results today (elimination of H. pylori in 80-90% of treated patients) is triple therapy [Axon ATR. Scand J
Gastroenterol 1989;24(suppl 160) :35-38.]. The therapy is a combination of a bismuth preparation, metronidazole and amoxicillin or tetracycline. However, the dosage regimen involves many tablets and there is a need of administration several times per day. This is difficult for the patient to follow and compliance has been shown to be important to achieve the high eradication rates. Adverse effects, mainly due to metronidazole or bismuth are very common. About 30% of the patients have reported side effects [Axon ATR, Scand J Gastroenterol 1989;24(suppl 160):35- 38].
Monotherapy of different antibiotics which are known to have good effect in vitro against H. pylori is insufficiently effective in vivo. Amoxicillin, for example, eradicates H.pylori only in about 20% of treated patients. Combination of two drugs give higher eradication rates than monotherapy. Bismuth preparations (bismuth subsalicyclate or colloidal bismuth subcitrate) in combination with amoxicillin eradicated H.pylori in 44 % of treated patients, bismuth + metronidazole, amoxicillin + tinidazole and amoxicillin + metronidazole in about 55 % of the patients, respectively [Chiba N, Rademaker JW, Rao BV et al. Gut 1991;32:A1220-1221 Abstract].
Antibacterial agents have also been combined with acid secretion inhibitors. Combinations with histamin -blockers show no improved efiect. Proton pump inhibitors e g omeprazole, which have very little anti-H .pylori efiect on its own show a synergistic effect in combination with antibiotics. A dose of 750 mg amoxicillin twice daily with 40 mg omeprazole once daily was reported to eradicate H.pylori in 54% of the patients [Unge P, Eriksson K, Bergman B. et al. Gastroenterol
1992;102(4);A183(abstract)]. Any explanation for this synergistic effect is not yet known, according to available information.
Many antibiotics have relatively short duration of action and are given 3-4 times a day. Attempts to prolong the action by use of prolonged release products have generally been unsuccessful because the absorption of the antibiotic from the gastrointestinal tract is poor when administered in slow release form [Delgado Charro MB, Vila Jato JL. Int J Pharm 1992;78;35-41] Instead antibiotics are given in rapidly absorbed formulations, e g tablets or capsules. In order to achieve sufficiently long duration of action higher doses are given.
In all previous studies on H.pylori eradication rapidly available dosage forms of the antibacterial agents have been used and attempts have been made to increase the success rate by using very high doses of antibacterials as well as proton pump inhibitors. For example, 82% of treated patients were eradicated after 10 days therapy of 40 mg omeprazole twice daily in combination with 1 g amoxicillin twice daily followed by 6 weeks monotherapy of 20 mg omeprazole once daily. [Bayerdδrffer E, Marines GA, Sommer A et al. Gastroenterol 1992;102(4):A38(abstract)].
Outline of the invention We have discovered that the effectiveness of the treatment can be improved in an entirely different way, namely by administration of the antibacterial agents in prolonged release formulations and administer the formulations in such a way that they stay in the stomach several hours. It is not yet known if the H.pylori bacterias are accessible for treatment by antibacterial agents in the stomach or if the drug has to be absorbed and reach the bacterias via the blood circulation. The improved effect of formulations according to this invention may indicate that a local effect in the stomach is important.
Examples of formulations with prolonged gastric residence time are bioadhesive systems which interact with mucus or the mucosa. Another way to prolong the residence time is swelling systems which expand in contact with the gastric fluid to a size which does not allow the system to pass through the pylorus. Further examples are formulations with very high density or systems which float on the gastric contents. It has also been observed that large non-disintegrating tablets or capsules can be retained for several hours in the stomach. The retention time in the stomach is especially prolonged when the tablet or capsule is administered together with food due to the sieving function of pylorus when the stomach is in the digestive mode [Davis SS, Hardy JG, Taylor MJ et al. Int J Pharm 1984;21:331-340]. Food also retards the emptying of tablets or pellets, but the effect is less pronounced. The critical size is reported to be about 7 mm [Khosla R. Nottingham: University of Nottingham, 1987. (Diss).]
The drug should be released within 1-24 h, preferably 1-6 h. To achieve an effective treatment of H.pylori infection the product should remain in the stomach at least 2-4 h, preferably more than 6 h. The major part of the drug should be released before the tablet leaves the stomach. The drugs suitable for the preparations according to the invention are e.g. ampicillin, amoxicillin, benzylpenicillin , phenoxymethylpenicillin, bacampicillin, pivampicillin, carbenicillin, cloxacillin, cyclacillin, dicloxacillin, methicillin, oxacillin, piperacillin, ticarcillin,flucloxacillin, cefuroxime, cefetamet, cefetrame, cefixime, cefoxitin, ceftazidime, ceftizoxime, latamoxef, cefoperazone, ceftriaxone, cefsulodin, cefotaxime, cephalexin, cefaclor, cefadroxil. cefalothin, cefazolin, cefpodoxime, ceftibuten, aztreonam, tigemonam, erythromycin, dirithromycin, roxithromycin, azithromycin, clarithromycin, clindamycin, paldimycin, lincomycin, vancomycin, spectinomycin, tobramycin, paromomycin, metronidazole, tinidazole, ornidazole, amifloxacin, cinoxacin, ciprofloxacin, difloxacin, enoxacin, fleroxacin, norfloxacin, ofloxacin, temafloxacin, doxycycline, minocycline, tetracycline, chlortetracycline, oxytetracycline, methacycline, rolitetracyclin, nitrofurantoin, nalidixic acid, gentamicin, rifampicin, amikacin, netilmicin, imipenem, cilastatin, chloramphenicol, furazolidone, nifuroxazide, sulfadiazin, sulfametoxazol, bismuth subsalicylate, colloidal bismuth subcitrate, gramicidin, mecillinam, cloxiquine, chlorhexidine, dichlorobenzylalcohol, methyl-2-pentylphenol. The active agents could be in standard forms or used as salts, hydrates, esters etc. A combination of two or more of the above listed drugs may be preferable, for example to ininimize the risk for developing resistance. The antimicrobial agents can also be combined with other drugs used in the treatment of acid related diseases e.g. acid pump inhibitors or Hn-blockers, such as for example omeprazole.
Possible formulations to be used are large non-disintegrating tablets or capsules e.g. inert matrix tablets [Hui H, Robinson JR, Lee NHL. Design and fabrication of Oral Controlled Delivery Systems. In: Robinson JR, Lee NHL, eds. Controlled Drug Delivery. Fundamentals and applications. New York: Marcel Dekker, Inc, 1987:373-432], osmotic pumps [Davis SS, Fara JW. Osmotic pumps. In: Hardy JG, Davis SS, Wilson CG, eds. Drug Delivery to the Gastrointestinal Tract. Chichester: Ellis Horwood Limited, 1989:97-109.] and membrane-coated tablets. Further, swelling systems [Banker, US Patent + no 261,242,] floating systems [Davis SS, Stockwell AF, Taylor MJ et al. Pharm Res 1986;3:208-213.], [Washington N, Wilson CG, Greaves JL et al. Scand J Gastroenterol 1988;23:920-924], formulations with high density [Devereux JE, Newton JM, Short MB. J Pharm Pharmacol 1990;42:500-501] and mucoadhesive systems [Junginger HE. Pharm Ind 1991;53:1056-1065] prepared from e.g. polycarbophil, polyacrylic acid, methylcellulose, polyethylene oxide, chitosan, tragacanth, sodium carboxymethyl cellulose can be used.
An example from the above listed formulations is the inert porous matrix tablet which is obtained by mixing the drug with waxes or water insoluble polymers and with fillers and binders. Paraffin, polyvinylchloride, ethylcellulose, stearylic alcohol, cetylic alcohol, carnauba wax, polyethylene, polyvinyl acetate, polymethyl methacrylate could be used as suitable diffusion retarding compounds. Other excipients used in the preparations of such tablets are e.g. lactose, mannitol, calcium phosphates, magnesium stearate, hydroxypropyl methylcellulose, methylcellulose, polyvinylpyrrolidone, aluminium silicate, sodium carbonate, potassium phosphate or other suitable materials.
Examples
It is the object of the present invention to provide an extended- release preparation with prolonged gastric residence time after oral administration, containing one or more antimicrobial agents.
Example 1: g
Amoxicillin sodium 830
Paraffin 500 Ethylcellulose 60
Magnesium stearate 28.8
Amoxicillin sodium was mixed in a planetary mixer for 5 minutes with paraffin. The resultant mixture was then moistened for 5 minutes with a solution of ethylcellulose in isopropanol and dried. The granulate was milled through a 1.0 mm sieve and lubricated for 2 minutes with magnesium stearate.
The granulate was compressed to tablets on a tabletting machine fitted with 13 mm punches. Each tablet contained 415 mg amoxicillin sodium. The release profile of the drug is shown in Figure 1.
Example 2: g
Amoxicillin trihydrate 215.6
Paraffin 250
Sodium carbonate 209
Ethylcellulose 30 Magnesium stearate 14.1 The composition according to Example 2 was formed to modified release tablets containing 375 mg of amoxicillin/tablet. The tablet were prepared in the following way:
Amoxicillin trihydrate, paraffin and sodium carbonate were mixed for 5 minutes in a planetary mixer. The remaining process was made according to Example 1. The release profile of the drug is shown in Figure 2.
Example 3 g
Amoxicillin trihydrate 215
Tripotassium phosphate 209
Polyvinylpyrrolidone 20 Magnesium stearate 20
Compressed into tablets after granulation and drying as in Example 1. The tablets were coated with a porous membrane coating consisting of polyvinyl chloride in acetone according to [Kallstrand G, Ekman B. J Pharm Sci 1983;72(7):772-775].
Micronized sucrose (particle size less than 10 um) was suspended in the polymer solution. Coating was achieved by spraying the suspension on a moving bed of tablets with an airless sprayer. Coating was continued until the weight if the coat on each tablet was 50 mg. Example 4: g
Amoxicillin trihydrate 244
Ethylcellulose 268
Chitosan 366
Hydrochloric acid 0,13
*
Water purified q.s.
*
Ethanol q.s.
Used in the manufacture of pellets but removed during subsequent processing
The bioadhesive pellets were manufactured using conventional fluid-bed coating technology. Amoxicilhn trihydrate was successively coated with solutions containing chitosan and ethylcellulose, respectively.

Claims

Claims
1. An oral formulation containing active materials for treatment of infections in the upper gastrointestinal tract characterized in that the formulation is retained in the stomach for a prolonged time whereby the active materials are released continuously during said time.
2. A formulation according to claim 1 where the preferred retention time is at least 1 h during which period the active materials are released continuously.
3. A formulation according to claim 1, wherein the formulation contains one or more antibacterial agents.
4. A formulation according to claim 1 where the infection is caused by Helicobacter pylori.
5. A formulation according to claim 1 wherein the active substance is amoxicillin.
6. A formulation according to claim 1 comprising a combination of two or more active agents.
7. A formulation according to claim 1 where the dosage form has bioadhesive properties.
8. A formulation according to claim 1 consisting of a non- disintegrating prolonged release formulation containing antibacterial agents.
9. A formulation according to claim 8 wherein the size is not less than 7 mm.
10. A formulation according to claim 9 where the release of the active compound is controlled by a non-disintegrating membrane.
11. A formulation according to claim 9 where the formulation is an inert porous matrix.
12. A process for the manufacture of a preparation according to claim 11 wherein the active substance is mixed with polymers or materials in an amount exceeding 10% of the weight of the mixture and the resulting mixture is compressed into a tablet.
13. A process according to claim 12 wherein the tablet is heated to a temperature above the melting point of the waxy material to retard the release profile and improve the mechanical strength of the tablet.
14. Use of a formulation according to claim 1 in the preparation of an active dosage form for the treatment of infections in the upper gastrointestinal tract.
15. Use of a formulation according to claim 1 together with acid secretion inhibitors.
16. Use of a formulation according to claim 1 together with proton pump inhibitors.
17. Use according to claim 16 wherein the proton pump inhibitor is omeprazole.
PCT/SE1993/000521 1992-06-24 1993-06-11 An oral formulation for gastric antibacterial treatment as well as a process thereof and the use WO1994000112A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45178/93A AU4517893A (en) 1992-06-24 1993-06-11 An oral formulation for gastric antibacterial treatment as well as a process thereof and the use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201930A SE9201930D0 (en) 1992-06-24 1992-06-24 GASTRIC ANTIBACTERIAL TREATMENT
SE9201930-6 1992-06-24

Publications (1)

Publication Number Publication Date
WO1994000112A1 true WO1994000112A1 (en) 1994-01-06

Family

ID=20386583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1993/000521 WO1994000112A1 (en) 1992-06-24 1993-06-11 An oral formulation for gastric antibacterial treatment as well as a process thereof and the use

Country Status (5)

Country Link
AU (1) AU4517893A (en)
IS (1) IS4030A (en)
SE (1) SE9201930D0 (en)
SI (1) SI9300330A (en)
WO (1) WO1994000112A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0754465A1 (en) * 1994-04-01 1997-01-22 TSUMURA & CO. Process for producing sustained-release tablets and enteric tablets
WO1998040054A1 (en) * 1997-03-12 1998-09-17 Astra Aktiebolag (Publ) An enteric coated oral dosage form comprising sodium amoxycillin
WO1998052547A1 (en) * 1997-05-24 1998-11-26 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Gastroretentive controlled release microspheres for improved drug delivery
US5948773A (en) * 1993-09-09 1999-09-07 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
EP0941064A1 (en) * 1996-11-17 1999-09-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED RELEASE OF beta -LACTAM ANTIBIOTICS
US6068859A (en) * 1994-05-06 2000-05-30 Pfizer Inc. Controlled-release dosage forms of Azithromycin
US6428813B1 (en) 1997-03-25 2002-08-06 Takeda Chemical Industries, Ltd. Gastrointestinal mucosa-adherent pharmaceutical composition
US6694692B2 (en) 1998-10-16 2004-02-24 Francesco Piccone Modular formwork elements and assembly
WO2004087175A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
WO2005065685A1 (en) * 2004-01-06 2005-07-21 Panacea Biotec Ltd. Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer
WO2006031420A2 (en) * 2004-08-27 2006-03-23 Spherics, Inc. Multi-layer tablets and bioadhesive dosage forms
WO2007110875A1 (en) * 2006-03-24 2007-10-04 Panacea Biotec Ltd. Antibiotic compositions of modified release and process of production thereof
WO2008030141A1 (en) * 2006-09-06 2008-03-13 Bosnalijek, Pharmaceutical And Chemical Industry, Joint Stock Company Use of nifuroxazide in the form of a component of a combined drug therapy for treating diseases associated with helicobacter pylori and a curing method for eradicating a causative agent
USRE45198E1 (en) 1996-01-04 2014-10-14 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455475A2 (en) * 1990-05-03 1991-11-06 Reckitt And Colman Products Limited Use of triclosan in the treatment of diseases of the gastrointestinal tract
WO1991019486A1 (en) * 1990-06-14 1991-12-26 Kalmo Enterprises, Inc. Stable aqueous drug suspensions
EP0490450A1 (en) * 1990-12-11 1992-06-17 Yamanouchi Europe B.V. Heterocyclic carboxylic esters, methods for their preparation and their use for the preparation of gastrointestinal medicines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455475A2 (en) * 1990-05-03 1991-11-06 Reckitt And Colman Products Limited Use of triclosan in the treatment of diseases of the gastrointestinal tract
WO1991019486A1 (en) * 1990-06-14 1991-12-26 Kalmo Enterprises, Inc. Stable aqueous drug suspensions
EP0490450A1 (en) * 1990-12-11 1992-06-17 Yamanouchi Europe B.V. Heterocyclic carboxylic esters, methods for their preparation and their use for the preparation of gastrointestinal medicines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURRENT OPINION IN GASTROENTEROLOGY, Volume 8, 1992, C.S. GOODWIN et al., "Peptic Ulcer Disease and Helicobacter Pylori Infection", page 122 - page 127. *
DIALOG INFORMATION SERVICES, File 154, Medline, Dialog Accession No. 08302546, MEDLINE Accession No. 93012546, RUNE S., "Helicobacter Pylori, Peptic Ulcer Disease and Inhibition of Gastric Acid Secretion"; & DIGESTION (ZWITSERLAND), 1992, 51 Suppl. 1, p.11-6. *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0995447A1 (en) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
US6319904B1 (en) 1993-09-09 2001-11-20 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
US5948773A (en) * 1993-09-09 1999-09-07 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
EP0754465A4 (en) * 1994-04-01 1998-05-06 Tsumura & Co Process for producing sustained-release tablets and enteric tablets
EP0754465A1 (en) * 1994-04-01 1997-01-22 TSUMURA & CO. Process for producing sustained-release tablets and enteric tablets
US7108865B2 (en) 1994-05-06 2006-09-19 Pfizer Inc Controlled-release dosage forms of azithromycin
EP0758244B2 (en) † 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
US6068859A (en) * 1994-05-06 2000-05-30 Pfizer Inc. Controlled-release dosage forms of Azithromycin
USRE45198E1 (en) 1996-01-04 2014-10-14 The Curators Of The University Of Missouri Omeprazole solution and method for using same
EP0941064A1 (en) * 1996-11-17 1999-09-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED RELEASE OF beta -LACTAM ANTIBIOTICS
US6399086B1 (en) 1996-11-17 2002-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical preparations for the controlled release of beta-lactam antibiotics
EP0941064A4 (en) * 1996-11-17 2001-12-12 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED RELEASE OF beta -LACTAM ANTIBIOTICS
WO1998040054A1 (en) * 1997-03-12 1998-09-17 Astra Aktiebolag (Publ) An enteric coated oral dosage form comprising sodium amoxycillin
US6428813B1 (en) 1997-03-25 2002-08-06 Takeda Chemical Industries, Ltd. Gastrointestinal mucosa-adherent pharmaceutical composition
US6207197B1 (en) 1997-05-24 2001-03-27 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Gastroretentive controlled release microspheres for improved drug delivery
GB2341550B (en) * 1997-05-24 2002-01-09 West Pharm Serv Drug Res Ltd Gastroretentive controlled release microspheres for improved drug delivery
GB2341550A (en) * 1997-05-24 2000-03-22 West Pharm Serv Drug Res Ltd Gastroretentive controlled release microspheres for improved drug delivery
WO1998052547A1 (en) * 1997-05-24 1998-11-26 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Gastroretentive controlled release microspheres for improved drug delivery
US6694692B2 (en) 1998-10-16 2004-02-24 Francesco Piccone Modular formwork elements and assembly
WO2004087175A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EA012296B1 (en) * 2004-01-06 2009-08-28 Панацея Биотек Лтд. Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer
WO2005065685A1 (en) * 2004-01-06 2005-07-21 Panacea Biotec Ltd. Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006031420A3 (en) * 2004-08-27 2006-11-30 Spherics Inc Multi-layer tablets and bioadhesive dosage forms
WO2006031420A2 (en) * 2004-08-27 2006-03-23 Spherics, Inc. Multi-layer tablets and bioadhesive dosage forms
WO2007110875A1 (en) * 2006-03-24 2007-10-04 Panacea Biotec Ltd. Antibiotic compositions of modified release and process of production thereof
WO2008030141A1 (en) * 2006-09-06 2008-03-13 Bosnalijek, Pharmaceutical And Chemical Industry, Joint Stock Company Use of nifuroxazide in the form of a component of a combined drug therapy for treating diseases associated with helicobacter pylori and a curing method for eradicating a causative agent

Also Published As

Publication number Publication date
SI9300330A (en) 1993-12-31
AU4517893A (en) 1994-01-24
IS4030A (en) 1993-12-25
SE9201930D0 (en) 1992-06-24

Similar Documents

Publication Publication Date Title
WO1994000112A1 (en) An oral formulation for gastric antibacterial treatment as well as a process thereof and the use
JP3292732B2 (en) Sustained release composition for basic drugs with low solubility
US6730320B2 (en) Tetracycline antibiotic product, use and formulation thereof
US5559096A (en) Pharmaceutical compositions against gastric disorders
JP3725542B2 (en) Picosulfate dosage form
US20030203878A1 (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
RU2590979C2 (en) Formulations of l-menthol, consisting of plurality of particles, and related methods
BG97458A (en) Preparations and methods for the treatment of the alimentary canal
CA2494015C (en) Antibiotic product, use and formulation thereof
JP3633936B2 (en) Senna dosage form
JP2001519379A (en) Delayed total release gastrointestinal drug delivery system
US20140154317A1 (en) Pharmaceutical Composition for Treatment of Helicobacter Pylori Associated Diseases
JP4981208B2 (en) Taurolidine and / or taurultam for infectious ulcers or gastritis
WO1998040054A1 (en) An enteric coated oral dosage form comprising sodium amoxycillin
UA120249C2 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
US9144548B2 (en) Antibiotic product, use and formulation thereof
US8313775B2 (en) Antibiotic product, use and formulation thereof
US8313776B2 (en) Antibiotic product, use and formulation thereof
CA2533358A1 (en) Antibiotic product, use and formulation thereof
JPH08502281A (en) Pharmaceutical compositions containing antibacterial agents and antibiotics
US8246996B2 (en) Antibiotic product, use and formulation thereof
CA2538064C (en) Antibiotic product, use and formulation thereof
JPH0248525A (en) Remedy for peptic ulcer
TR201511982A2 (en) Antibacterial formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase